Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study-Reference-Cited by-同舟云学术

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:9368-9372
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wang Michael L.¹,Shah Nirav N.²,Jurczak Wojciech³,Zinzani Pier Luigi⁴,Eyre Toby A.⁵,Cheah Chan Y.⁶,Ujjani Chaitra S.⁷,Koh Youngil⁸,Izutsu Koji⁹,Gerson James N.¹⁰,Flinn Ian W.¹¹,Tessoulin Benoit¹²,Alencar Alvaro J.¹³,Ma Shuo¹⁴,Lech-Marańda Ewa¹⁵,Rhodes Joanna M.¹⁶,Patel Krish¹⁷,Woyach Jennifer A.¹⁸,Lamanna Nicole¹⁹,Wang Yucai²⁰,Tam Constantine S.²¹,Seymour John F.²¹,Munir Talha²²,Nagai Hirokazu²³,Hernandez-Ilizaliturri Francisco²⁴,Kumar Anita²⁵,Zelenetz Andrew D.²⁵,Jain Preetesh²⁶,Nair Binoj²⁷,Tsai Donald E.²⁷,Balbas Minna²⁷,Walgren Richard A.²⁷,Abada Paolo B.²⁷,Wang Chunxiao²⁸,Zhao Junjie²⁷,Mato Anthony R.²⁵

Affiliation:

1. 1MD Anderson Cancer Center, Houston, TX

2. 2Medical College of Wisconsin, Brookfield, WI

3. 3Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

4. 4Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy

5. 5Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

6. 6Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

7. 7Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

8. 8Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

9. 9National Cancer Center Hospital, Tokyo, Japan

10. 10Lymphoma Program, Abramson Cancer Center, Philadelphia, PA

11. 11Sarah Cannon Research Institute, Nashville, TN

12. 12Hematology Department, Nantes University Hospital, Nantes, France

13. 13Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL

14. 14Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

15. 15Institute of Hematology and Transfusion Medicine, Warsaw, Poland

16. 16Northwell Health Cancer Institute, New Hyde Park, NY

17. 17Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA

18. 18The Ohio State University Comprehensive Cancer Center, Columbus, OH

19. 19New York-Presbyterian/ Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

20. 20Division of Hematology, Mayo Clinic, Rochester, MN

21. 21Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia

22. 22Department of Haematology, St James's University Hospital, Leeds, United Kingdom

23. 23Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

24. 24Roswell Park Cancer Institute, Buffalo, NY

25. 25Memorial Sloan Kettering Cancer Center, New York, NY

26. 26Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

27. 27Loxo@Lilly, Indianapolis, IN

28. 28Eli Lilly and Company, Indianapolis, IN

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib;Blood Advances;2024-08-28

2. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma;Biomarker Research;2024-06-18

3. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor;Advances in Therapy;2024-03-18

4. Bruton’s Tyrosine Kinase Inhibitors: Recent Updates;International Journal of Molecular Sciences;2024-02-12

5. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study;Journal of Clinical Oncology;2023-12-10